Rhizoma drynariae total flavonoids inhibit the inflammatory response and matrix degeneration via MAPK pathway in a rat degenerative cervical intervertebral disc model - 16/04/21
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 9 |
| Iconographies | 7 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Rhizoma drynariae total flavonoids (RDTF) are extracted from Drynaria fortunei J. Sm (D. fortunei), which was a Chinese herb commonly used to treat fractures and bruises. Modern pharmacological studies indicate flavonoids have anti-inflammatory effect in clinical practice. However, its active ingredients and the mechanisms of action are far from clear. The present study aims to determine whether RDTF can protect against intervertebral disc degeneration in a rat cervical intervertebral disc model and investigate the associated molecular mechanisms. Sprague Dawley (SD) rats were randomized into five groups: control group (CG, n = 8), intervertebral disc degeneration group (NG, n = 8), low-dose RDTF-treated group (LG, n = 8), medium-dose RDTF-treated group (MG, n = 8), and high-dose RDTF-treated group (HG, n = 8). Hematoxylin and eosin (HE) staining, immunohistochemistry (IHC), immunofluorescence, ELISA, Western blot and quantitative real time PCR (qRT-PCR) assays were used to investigate inflammatory, catabolic factors and the latent regulatory mechanism of the effects of RDTF on intervertebral disc cells. HE staining showed disc degeneration in all groups except CG, and the function was restored after RDTF treatment. IHC, Western blot, qRT-PCR, immunofluorescence and ELISA results showed that RDTF prevented intervertebral disc degeneration by suppressing mitogen-activated protein kinase (MAPK) pathway, which reduced expression of intracellular matrix metalloproteinases (MMPs), such MMP3, MMP13, and inflammatory factors including interleukin-1β (IL-1β), tumour necrosis factor-α (TNF-α). Notably RDTF inhibited extracellular matrix (ECM) degeneration by increasing expression of aggrecan and collagen type II and preventing the upregulation of collagen type I and III. It suggests that RDTF has a potential therapeutic effect on cervical spondylosis.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
This diagram illustrates highlights of the work that Rhizoma drynaria flavonoids may inhibit intervertebral disc degeneration. Rhizoma drynaria flavonoids through MAPK pathway regulated the expression of MMP-13, MMP-3 LI-1β, TNF-α, Collagen I, Collagen III, Collagen II and aggrecan. Experimental methods included Hematoxylin and Eosin (HE) staining, Immunohistochemistry (IHC), Immunofluorescence, Elisa, Western blot and Quantitative real time PCR (qRT-PCR).
Highlights |
• | RDTF had inhibitory effect on inflammatory factors including interleukin-1β (IL-1β), tumour necrosis factor-α (TNF-α). |
• | RDTF attenuated ECM degradation in NP cells. |
• | RDTF improves intervertebral disc degeneration in vivo and may become a new potential therapeutic for cervical spondylosis. |
Keywords : Rhizoma drynariae total flavonoids, Intervertebral disc degeneration, Model, Inflammation, Intracellular matrix metalloproteinases, Mitogen-activated protein kinase
Plan
Vol 138
Article 111466- juin 2021 Retour au numéro
Article précédent
- Impact of renin-angiotensin system inhibitors on mortality during the COVID Pandemic among STEMI patients undergoing mechanical reperfusion: Insight from an international STEMI registry
- Giuseppe De Luca, Miha Cercek, Lisette Okkels Jensen, Oliver Bushljetikj, Lucian Calmac, Tom Johnson, Montserrat Gracida Blancas, Vladimir Ganyukov, Wojtek Wojakowski, Clemens von Birgelen, Alexander IJsselmuiden, Bernardo Tuccillo, Francesco Versaci, Jurrien Ten Berg, Mika Laine, Tim Berkout, Gianni Casella, Petr Kala, Bernabé López Ledesma, Victor Becerra, Roberto Padalino, Andrea Santucci, Xavier Carrillo, Alessandra Scoccia, Giovanni Amoroso, Arpad Lux, Tomas Kovarnik, Periklis Davlouros, Gabriele Gabrielli, Xacobe Flores Rios, Nikola Bakraceski, Sébastien Levesque, Vincenzo Guiducci, Michał Kidawa, Lucia Marinucci, Filippo Zilio, Gennaro Galasso, Enrico Fabris, Maurizio Menichelli, Stephane Manzo, Gianluca Caiazzo, Jose Moreu, Juan Sanchis Forés, Luca Donazzan, Luigi Vignali, Rui Teles, Pierfrancesco Agostoni, Francisco Bosa Ojeda, Heidi Lehtola, Santiago Camacho-Freiere, Adriaan Kraaijeveld, Ylitalo Antti, Gabriella Visconti, Iñigo Lozano Martínez-Luengas, Bruno Scheller, Dimitrios Alexopulos, Raul Moreno, Elvin Kedhi, Giuseppe Uccello, Benjamin Faurie, Alejandro Gutierrez Barrios, Fortunato Scotto Di Uccio, Bor Wilbert, Giuliana Cortese, Maurits T. Dirksen, Guido Parodi, Monica Verdoia
- A novel histone deacetylase inhibitor MPT0L184 dysregulates cell-cycle checkpoints and initiates unscheduled mitotic signaling
- Ting-Yu Chang, Kunal Nepali, Yi-Ying Chen, Yu-Chen S.H. Yang, Kai-Cheng Hsu, Yun Yen, Shiow-Lin Pan, Jing-Ping Liou, Sung-Bau Lee
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?